Creative Imagery Committee
-
PAAB has formed a committee of industry experts on creative imagery use in pharmaceutical advertising. The first meeting is scheduled for April 12th. Please follow this topic or check back occasionally to see updates from the committees. You can also check out the PAAB website for more details.
-
@jennifer-carroll has there been any further developments on the Creative Imagery Committee? I searched the PAAB web site but did not find anything further on this topic.
-
@jennifer-carroll Checking in on this again. Any developments?
-
Hello @constance
Apologies for the delay. The committee will have it's 3rd all committee meeting in early January. During the meeting, the members will go over examples that touch on several segments of the creative spectrum. Those examples and the ensuing discussion will likely be incorporated into a guidance document or advisory. We are optimistic that this process will promote alignment between PAAB and industry.
-
@jennifer-carroll if there is an opportunity for us to contribute to this (send in our examples), please let me know.
-
Hey @constance
Always happy to have more examples to discuss. If you’d like to send examples for the group to discuss, please email them to me at jenniferc@paab.ca.
What we would require is:
• Confirmation from the sponsor that the content can be discussed and shared with the committee
• Confirmation from the sponsor that all content discussed can be shared externally as part of training documents
• Any information you can share about the campaign such as “what are the primary and secondary messages the campaign hopes to convey”
• If the creative went through iterations, provide the iterations (iterations with PAAB or outside of PAAB such as through the internal Canadianization process or within the agency).
• If you have internally developed creative that was not part of a sponsor project that you think would make for good discussions, we can look at those as wellThe committee will not be evaluating the merits of any past decisions or evidence and in most cases the discussions will be brand agnostic so that the discussion stays focused on assessing creative elements.
As the committee is meeting in early January, we'd encourage sending content before then.
